surpass trial tirzepatide LLY says #semaglutide Sustain-1 $NVO most comparable for upcoming #tirzepatide Surpass-1 data Overview of the SURPASS clinical

The first randomised controlled trial of semaglutide for alcohol use disorder, published in JAMA Psychiatry in 2025, found that people taking low doses had fewer heavy drinking days, fewer cravings, and reduced alcohol intake compared to placebo

March 31 (Reuters) - Novo Nordisk on Tuesday cut the prices of its diabetes and weight-loss drugs Ozempic and Wegovy by as much as 36% and 48% in India, its second such move, to fend off competition

This systematic review aims to synthesize existing evidence on the effects of GLP-1 RAs on mental health outcomes, including both potential therapeutic benefits across various psychiatric disorders and the risk of associated adverse mental health effects

Looking to order MOUNJARO 10mg KwikPen online

TrimRX connects you to licensed providers for GLP-1 meds